TNGX

In the past six months, Tango Therapeutics' stock (TNGX) saw a substantial increase of 206.60% from October 2025 to October 2026, and a +225.3% change over the last year. A significant event occurred on June 8, 2026, when the stock surged by 52.97% following the announcement of positive initial Phase 1/2 data for its PRMT5 inhibitor, vopimetostat, combined with Revolution Medicines' RAS(ON) inhibitors, showing a 92% objective response rate in pancreatic cancer and leading to analyst price target raises. However, the stock also experienced downward movements, including a -0.8% change in the month leading up to October 9, 2026. On August 11, 2026, the company reported Q2 2026 financial results with zero revenue and a widened net loss, causing a roughly 5% stock drop on August 12, 2026, and a 15% drop over 30 days. Other recent news includes inducement grants, participation in a healthcare conference, and executive option exercises and share sales in September 2026.